Navigation Links
Gen-Probe Reports Financial Results for the Fourth Quarter of 2011
Date:2/14/2012

about our expectations, beliefs, plans, objectives, assumptions or future events or performance, including those under the heading "2012 Financial Guidance," are not historical facts and are forward-looking statements.  These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would.  For example, statements concerning Gen-Probe's financial condition, possible or expected results of operations, the development and commercialization of new products, regulatory approvals, future milestones, growth opportunities, market trends, and management plans are forward-looking statements.  Forward-looking statements are not guarantees of performance.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied.  Some of these risks, uncertainties and assumptions include but are not limited to: (i) the risk that we may not achieve our expected 2012 financial targets, (ii) the risk that we may not integrate acquisitions, such as Tepnel, Prodesse and GTI, successfully, (iii) the possibility that the market for the sale of our new products, such as our PANTHER system and PROGENSA PCA3, APTIMA HPV and APTIMA trichomonas assays, may not develop as expected, (iv) the enhancement of existing products and the development of new products may not proceed as planned, (v) the risk that investigational products, including those now in US clinical trials, may not be approved by regulatory authorities or become commercially available in the time frame we anticipate, or at all, (vi) the risk that we may not be able to compete effectively, (vii) the risk that we may not be able to maintain our current corporate collaborations or enter into new ones, (viii) our dependence on Novartis and other third parties for the distribution of some of
'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Gen-Probe Reports Financial Results for the Second Quarter of 2011
2. Gen-Probe to Webcast Two Upcoming Investor Presentations
3. Gen-Probe Announces Webcast of First Quarter 2011 Earnings Conference Call
4. Gen-Probe Reports Financial Results for the Fourth Quarter and Full Year 2010
5. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2010 Earnings Conference Call
6. Gen-Probe to Webcast Presentation at the 29th Annual J.P. Morgan Healthcare Conference
7. Gen-Probe Acquires GTI Diagnostics for $53 Million in Cash
8. Gen-Probe Announces Webcast of Annual Briefing for Institutional Investors and Financial Analysts
9. Gen-Probe to Acquire Prodesse, Leader in Molecular Testing for Respiratory Infectious Diseases, for $60 Million in Cash Plus Potential Milestone Payments
10. Gen-Probe to Consolidate Industrial Assets Into New, Independent Company
11. Gen-Probe to Webcast Four Upcoming Investor Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Cynvenio, a cancer ... through the genomic analysis of tumor cells in the ... a web-based cancer decision support application powered by CollabRx, ... Cynvenio’s ClearID™ genomic test, Therapy Finder will provide breast ...
(Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
(Date:1/15/2014)... January 15, 2014 Two champions of ... their sponsorship of an annual competition for middle and ... access to, innovative STEM study. The competition presents students ... Tests of Engineering Aptitude, Mathematics, and Sciences is ...
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... Therapeutics, Inc.,(Nasdaq: TPTX ) today announced that ... in certain royalty amounts that may become payable to ... and tezampanel,should either or both gain regulatory approval. Specifically, ... points and the middle tier,royalty rate will be reduced ...
... Pa., Nov. 25 Tengion Inc., a clinical stage regenerative medicine ... that Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion, ... Tuesday, December 2, 2008 at 9:50 a.m. EST at The Palace ... , About Tengion , ...
... 25 /PRNewswire-Asia/ -- ScinoPharm, an active,pharmaceutical ingredient (API) ... 7,435,818 entitled "Novel Crystal Forms of Irinotecan,Hydrochloride." The ... hydrochloride and processes for their preparation as well ... of treating,metastatic carcinoma of the colon or rectum ...
Cached Biology Technology:TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel 2ScinoPharm Granted US Patent for Novel Crystal Forms 2
(Date:4/20/2014)... Mothers give a newborn baby a gift of ... system. But antibiotics, used to fend off infection, ... leaving already-vulnerable premature babies more susceptible to dangerous ... neonatology researchers at The Children,s Hospital of Philadelphia ... revealing how gut microbes play a crucial role ...
(Date:4/18/2014)... decades, scientists have used techniques like X-ray crystallography and ... into the atomic structure of molecules, but such efforts ... demand large quantities of a specific molecule and often ... making it all but impossible to peer into the ... those problems may soon be a thing of the ...
(Date:4/18/2014)... Durham, NC Seeds that sprout as soon as they,re ... plants need to be more careful. In the wild, a ... rainy day would risk disaster. More than just an insurance ... out that seed dormancy has long-term advantages too: Plants ... give rise to more species, finds in a team of ...
Breaking Biology News(10 mins):Study of gut microbes, antibiotics: Clues to improving immunity in premature infants 2MRI, on a molecular scale 2MRI, on a molecular scale 3Plants with dormant seeds give rise to more species 2
... antibiotic used to boost organ survival in transplant ... the heart against tissue damage following acute heart ... Journal of Molecular and Cellular Cardiology, the official ... researchers demonstrated for the first time that pretreatment ...
... to change their spots, but corals can change their skeletons, ... composition of the seawater around them. , That's the startling ... in the July issue of the journal Geology. , ... the first known case of an animal altering the composition ...
... University in St. Louis and their collaborators from Taiwan ... varieties and have determined that the crop was domesticated ... Jason Londo, Washington University in Arts & Sciences biology ... Washington University Spencer T. Olin Professor of Biology in ...
Cached Biology News:New study shows antibiotic may protect the heart 2Corals switch skeleton material as seawater changes 2Corals switch skeleton material as seawater changes 3Biologists find regions of rice domestication 2
Mouse Wnt-9b Affinity Purified Polyclonal Ab Keywords: Wnt 9b Protein Family: Cancer Stem Cell Markers, Wnt Ligands...
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
One-step, microplate or cuvet, colorimetric, linear detection range 6 mg/dL to 100mg/dL. Procedure: 15 min....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
Biology Products: